#PortfolioNews
LightNews LightNews
ysioscapital.bsky.social
#PortfolioNews | Memo Therapeutics partners with CSL to advance recombinant polyclonal IgG, validating its DROPZYLLA® platform. 🚀🧬

👉 buff.ly/uCOUhUh

#YsiosPortfolio
February 9, 2026 at 3:19 PM
ysioscapital.bsky.social
🔬#Portfolionews | Inbiomotion’s MAF Test® included in 2025 SEOM-GEICAM-SOLTI guidelines for early #breast #cancer.

🎯 Advancing MAF-based clinical decision-making!
👉 buff.ly/zSld1qQ

#oncology #brestcancer
January 16, 2026 at 11:34 AM
furry-lover-owo.bsky.social
#rukis #redlantern #graysonreed #furry #art #furryart #painting #illustration #furrysfw #furrynovel #furrynovels #lutherdenholme #anthro #wip #novels #lgbt #furrylgbt #gay #hearttheft #darcy #Isidor #furrylgbt #OTBP #Shivah #OFFTHEBEATENPATH #illicitalliance #darcy #portfolionews
rukis.bsky.social Rukis @rukis.bsky.social · Oct 14
It's #portfolioday?!
My name is Rukis, and I'm a full-time Illustrator/Writer, waow! I work traditionally as well as digitally, and you can find my Historical Fiction Action/Adventure/Romance book series 'Red Lantern' as well as my Art Books here - furplanet.com/shop/categor...
October 14, 2025 at 6:24 PM
ysioscapital.bsky.social
#PortfolioNews I Study shows that #MAFTest® developed by our #portfolio company #Ibiomotion may save €105M in early #breast #cancer care.

🔗 Press release - buff.ly/8pAhrip
📄 Full publication here: lnkd.in/d3aUWmpp

#Oncology #HealthEconomics #BreastCancer
Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer
September 18, 2025 at 1:44 PM
ysioscapital.bsky.social
📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊

🔹Up to $2.2B incl. $117m upfront & milestones
🔹Global Phase 3 of VMX-C001 fully funded
🌍Step closer to market for a major unmet need

👉 buff.ly/aO4iHwV

#YsiosPortfolio #vc
VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment
September 16, 2025 at 10:08 AM
ysioscapital.bsky.social
#PortfolioNews I MAF Test® now adopted in top #Spanish hospitals to personalize early-stage #breast #cancer treatment. A major step for our #portfolio company #Inbiomotion !

👉 Full details here - buff.ly/aT4nwud

#BreastCancer #Oncology #PortfolioNews #MAFTest
July 18, 2025 at 11:27 AM
ysioscapital.bsky.social
#PortfolioNews | Proud to join the $135M Series B of our #portfolio company #SpliceBio, the largest round ever raised by a Spanish biotech 🚀

🧬 Advance SB-007 for #StargardtDisease
🔬Expand #GeneticMedicine pipeline

👉 buff.ly/jey8g9O

#VC #Biotech #Innovation #ProteinSplicing
June 11, 2025 at 9:16 AM
rubensebas.bsky.social
We are excited to support Adaptam’s mission to pioneer a new era of cancer #immunotherapy!

Learn more about Adaptam at: www.adaptamtx.com

#portfolionews #venturecapital #biotech #lifesciences #oncology #cancer #tumor #macrophages #glycobiology #glycans
ADAPTAM Therapeutics. The Next Era Of Cancer Immunotherapy.
Adaptam Therapeutics brings better therapies to oncology patients thanks to immunotherapies that target the immunosuppressive myeloid tumor.
www.adaptamtx.com
April 30, 2025 at 11:30 AM
ysioscapital.bsky.social
#PortfolioNews | #SparingVision receives #FDA support to launch Phase II trial of SPVN06 in #GeographicAtrophy

🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss

👉 buff.ly/m0BlGti

#GeneTherapy
April 22, 2025 at 2:44 PM
ysioscapital.bsky.social
#PortfolioNews I Our #portfolio company #Xeltis passes #EIC evaluation for potential €10M funding

🎯Developing regenerative implants to transform vascular surgery through natural tissue regeneration.

👉 buff.ly/rl7BP3W

#vc #innovation #dialysis
April 8, 2025 at 1:52 PM
ysioscapital.bsky.social
#PortfolioNews I We’re excited to share that our #portfolio company #Anacond Biomed has enrolled the first U.S. patient in its ATHENA trial.

🎯 Developing next-generation #neurothrombectomy devices for acute ischemic #stroke

👉 buff.ly/vXEDmrK

#vc #Spain #Medtech
April 4, 2025 at 1:36 PM
ysioscapital.bsky.social
#PortfolioNews | SpliceBio doses the first patient in the Phase 1/2 ASTRA study of SB-007, the first dual AAV #GeneTherapy for #StargardtDisease!

🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations.

👉 buff.ly/HvB3bPR

#VC
March 13, 2025 at 2:27 PM
ysioscapital.bsky.social
#PortfolioNews | Our #quoted company Mineralys Therapeutics (Nasdaq: #MLYS) reports #positive Phase 3 & 2 results for #lorundrostat in #hypertension & announces a $250M #PublicOffering to advance R&D!

👉 buff.ly/qeyUu5K
👉 buff.ly/g18zKmA

#ClinicalTrials
March 11, 2025 at 2:00 PM
ysioscapital.bsky.social
#PortfolioNews | NorthSea Therapeutics reports positive results from the Phase 2b ICONA trial of #Icosabutate in #MASH, published in the Journal of Hepatology!

📢 Read more: 👉 buff.ly/49eOq1j
📑 Full publication buff.ly/jZ9cXPW

#vc #fibrosis #metabolic
March 6, 2025 at 3:19 PM
ysioscapital.bsky.social
#PortfolioNews I Our portfolio company #Minoryx Therapeutics has dosed the first patient in the Phase 2a TREE study of #leriglitazone for #RettSyndrome! 🧠

🗓️ Results expected in H12026
👉 buff.ly/NycHUxI

#CNS #RareDisease #vc
March 5, 2025 at 1:02 PM
ysioscapital.bsky.social
#PortfolioNews | Adcendo receives #FDA clearance for Phase I trial of ADCE-T02

🎯 First-in-class #ADC targeting Tissue Factor in #SolidTumors.
🌍 Now recruiting in #Australia with #US expansion soon!

👉 Read more https://buff.ly/3Dc92qj

#Onclogy #vc
February 26, 2025 at 3:23 PM
ysioscapital.bsky.social
#PortfolioNews | Our #portfolio company Neurona Therapeutics plans Phase3 trial in H2 2025 for NRTX-1001, a #celltherapy for drug-resistant #epilepsy.

🔬 Encouraging early data: Up to 97% seizure reduction with no cognitive impairment

📢 Read more: https://buff.ly/3Dh9kfv

#VC
February 25, 2025 at 8:40 AM
ysioscapital.bsky.social
#PortfolioNews I NorthSea Therapeutics strengthens leadership & advances metabolic, cholestatic & fibrotic disease therapies.

🔬 Key trials ahead!

👉 https://buff.ly/3Quv4HV

#vc #MetabolicDiseases
February 21, 2025 at 2:08 PM
ysioscapital.bsky.social
#PortfolioNews I Our #portfolio company ONA Therapeutics strengthens leadership to accelerate first-in-class #ADCs targeting resistant #cancer cells & advancing toward #clinical development.

📢 Read more here https://buff.ly/4gK9vh3

#Oncology #Biotech #Pharma #YsiosPortfolio
February 20, 2025 at 9:02 AM
ysioscapital.bsky.social
#PortfolioNews I Our #quoted #portfolio company #Mineralys #MLYS completed Enrollment in Explore-CKD Phase 2 Trial of #Lorundrostat for the Treatment of #Hypertension in Subjects with Stage 2 to 3b chronic kidney disease #CKD and #Albuminuria

👉 https://buff.ly/4gqM4t2

#vc #ClinicalTrials
Mineralys Therapeutics Completes Enrollment – Ysios Capital
Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025
buff.ly
February 4, 2025 at 4:02 PM
rubensebas.bsky.social
Minoryx announces positive results for leriglitazone in the pivotal Ph2/3 trial for pediatric #cALD, a rare and life-threatening neurodegenerative disease. Minoryx plans to submit an EU marketing authorization application by mid 2025.

#portfolionews #biotech #CNS

www.minoryx.com/media/lerigl...
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy
www.minoryx.com
December 11, 2024 at 11:45 AM
ysioscapital.bsky.social
#PortfolioNews I We're proud to share that we have joined the oversubscribed $135M Series B financing of our #portfolio company #Adcendo👏

🎯Developing breakthrough #ADCs, for the #treatment of underserved #cancers

👉Full details buff.ly/3Z3JfYm

#vc #oncology #Innovation #biotech #Europe #investment
November 25, 2024 at 1:55 PM
ysioscapital.bsky.social
#PortfolioNews I Exciting news from AELIX Therapeutics! 🌍 Their HIV vaccine has been acquired by Gilead Sciences, a global leader in HIV research and innovation. 🔬

🎯 Committed to fostering the growth of the Spanish biotech ecosystem and driving positive societal impact.

👉 buff.ly/3OnAUtt
November 25, 2024 at 12:12 PM